Genome-wide CRISPR-Cas9 screen identifies microRNAs that regulate myeloid leukemia cell growth

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Wallace, Jared ^a   Hu, Ruozhen ^a   Mosbruger, Timothy L ^c   Dahlem, Timothy J ^b   Stephens, W Zac ^a   Rao, Dinesh S ^d   Round, June L ^a   O'Connell, Ryan M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; GENE IDENTIFICATION; GENE INTERACTION; GENOMICS; HUMAN; HUMAN CELL; MYELOID LEUKEMIA CELL LINE; ONCOGENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; CELL PROLIFERATION; CONSERVED SEQUENCE; GENETICS; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MOUSE; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CONSERVED SEQUENCE; CRISPR-CAS SYSTEMS; EVOLUTION, MOLECULAR; GENOMICS; HUMANS; LEUKEMIA, MYELOID; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84977617619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153689     Document Type: Article

References (23)

1. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(10):3945-50. doi: 10.1073/pnas.0800135105 PMID: 18308931; PubMed Central PMCID: PMC2268779.
2. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrozek K, Margeson D, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010; 116(18):3622-6. doi: 10.1182/blood-2010-05-283648 PMID: 20656931; PubMed Central PMCID: PMC2981481.
3. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011; 117(4):1121-9. doi: 10.1182/blood-2010-09-191312 PMID: 21045193; PubMed Central PMCID: PMC3056468.
4. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(32):14235-40. doi: 10.1073/pnas.1009798107 PMID: 20660734; PubMed Central PMCID: PMC2922591.
5. Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. The Journal of experimental medicine. 2010; 207(3):475-89. doi: 10.1084/jem.20090831 PMID: 20212066; PubMed Central PMCID: PMC2839143.
6. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature medicine. 2010; 16(1):49-58. doi: 10.1038/nm.2054 PMID: 19898489.
7. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(24):15524-9. doi: 10.1073/pnas.242606799 PMID: 12434020; PubMed Central PMCID: PMC137750.
8. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213):1258096. doi: 10.1126/science.1258096 PMID: 25430774.
9. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121):823-6. doi: 10.1126/science.1232033 PMID: 23287722; PubMed Central PMCID: PMC3712628.
10. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nature protocols. 2013; 8(11):2281-308. doi: 10.1038/nprot.2013.143 PMID: 24157548; PubMed Central PMCID: PMC3969860.
11. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343(6166):84-7. doi: 10.1126/science.1247005 PMID: 24336571; PubMed Central PMCID: PMC4089965.
12. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nature methods. 2014; 11(8):783-4. doi: 10.1038/nmeth.3047 PMID: 25075903.
13. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003; 17(1):120-4. doi: 10.1038/sj.leu.2402740 PMID: 12529668.
14. Andersson A, Eden P, Lindgren D, Nilsson J, Lassen C, Heldrup J, et al. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia. 2005; 19(6):1042-50. doi: 10.1038/sj.leu.2403749 PMID: 15843827.
15. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000; 96(12):3907-14. PMID: 11090077.
16. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. The Journal of experimental medicine. 2008; 205(3):585-94. doi: 10.1084/jem.20072108 PMID: 18299402; PubMed Central PMCID: PMC2275382.
17. Pedranzini L, Mottadelli F, Ronzoni S, Rossella F, Ferracin M, Magnani I, et al. Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment. Leukemia research. 2010; 34(10):1287-95. doi: 10.1016/j.leukres.2010.02.012 PMID: 20227111.
18. He Y, Jiang X, Chen J. The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 2014; 33(30):3887-93. doi: 10.1038/onc.2013.346 PMID: 23955084.
19. Gerloff D, Grundler R, Wurm AA, Brauer-Hartmann D, Katzerke C, Hartmann JU, et al. NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015; 29(3):535-47. doi: 10.1038/leu.2014.231 PMID: 25092144.
20. Zhang N, Wei X, Xu L. miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS letters. 2013; 587(15):2346-51. doi: 10.1016/j.febslet.2013.05.059 PMID: 23747308.
21. Wang DT, Ma ZL, Li YL, Wang YQ, Zhao BT, Wei JL, et al. miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis. Oncology reports. 2013; 30(1):492-8. doi: 10.3892/or.2013.2453 PMID: 23670238.
22. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. The Journal of clinical investigation. 2013; 123(6):2395-407. doi: 10.1172/JCI66553 PMID: 23676502; PubMed Central PMCID: PMC3668829.
23. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature cell biology. 2008; 10(5):593-601. doi: 10.1038/ncb1722 PMID: 18376396.